METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Deng, Tuo
Lin, Xueming
Wu, Shulin
Zhang, Zhenwei
Wu, Chin-Lee
Yan, Liying
Taplin, Mary-Ellen
Wang, Zongwei
Olumi, Aria
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP81-16
引用
收藏
页码：E1178 / E1179
页数：2
相关论文
共 50 条
  • [31] The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer
    Masaki Shiota
    Shusuke Akamatsu
    Shintaro Narita
    Takayuki Sumiyoshi
    Maki Fujiwara
    Takeshi Uchiumi
    Osamu Ogawa
    Tomonori Habuchi
    Masatoshi Eto
    The Pharmacogenomics Journal, 2021, 21 : 440 - 445
  • [32] Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
    Hamano, Itsuto
    Hatakeyama, Shingo
    Narita, Shintaro
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Sato, Hiromi
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy
    Huang, Haichao
    Chen, Shi
    Li, Wei
    Bai, Peide
    Wu, Xiurong
    Xing, Jinchun
    CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : E1036 - E1047
  • [34] Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
    Hamano, Itsuto
    Hatakeyama, Shingo
    Narita, Shintaro
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Sato, Hiromi
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    WORLD JOURNAL OF UROLOGY, 2019, 37 (11) : 2365 - 2373
  • [35] Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
    Itsuto Hamano
    Shingo Hatakeyama
    Shintaro Narita
    Masahiro Takahashi
    Toshihiko Sakurai
    Sadafumi Kawamura
    Senji Hoshi
    Masanori Ishida
    Toshiaki Kawaguchi
    Shigeto Ishidoya
    Jiro Shimoda
    Hiromi Sato
    Koji Mitsuzuka
    Tatsuo Tochigi
    Norihiko Tsuchiya
    Yoichi Arai
    Tomonori Habuchi
    Chikara Ohyama
    World Journal of Urology, 2019, 37 : 2365 - 2373
  • [36] Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer
    Iwamoto, Hiroaki
    Kano, Hiroshi
    Shimada, Takafumi
    Naito, Renato
    Makino, Tomoyuki
    Kadamoto, Suguru
    Yaegashi, Hiroshi
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadonoa, Yoshifumi
    Mizokami, Atsushi
    IN VIVO, 2021, 35 (02): : 1247 - 1252
  • [37] RNA Sequencing of Patient Matched Pre-Androgen Deprivation Therapy and Post-Androgen Deprivation Therapy Prostate Cancer Identifies Mechanisms of Progression to Castration-Resistant Prostate Cancer
    Moreno, Carlos S.
    Giuste, Felipe O.
    Pellegrini, Kathryn L.
    Sharma, Nitya V.
    Ouellet, Veronique
    Trudel, Dominique
    Mes-Masson, Anne-Marie
    Petros, John A.
    Saad, Fred
    Osunkoya, Adeboye O.
    LABORATORY INVESTIGATION, 2017, 97 : 245A - 245A
  • [38] RNA Sequencing of Patient Matched Pre-Androgen Deprivation Therapy and Post-Androgen Deprivation Therapy Prostate Cancer Identifies Mechanisms of Progression to Castration-Resistant Prostate Cancer
    Moreno, Carlos S.
    Giuste, Felipe O.
    Pellegrini, Kathryn L.
    Sharma, Nitya V.
    Ouellet, Veronique
    Trudel, Dominique
    Mes-Masson, Anne-Marie
    Petros, John A.
    Saad, Fred
    Osunkoya, Adeboye O.
    MODERN PATHOLOGY, 2017, 30 : 245A - 245A
  • [39] PSA KINETICS IN INITIAL ANDROGEN DEPRIVATION THERAPY IS A PROGNOSTIC FACTOR IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Hamano, Itsuto
    Hatakeyama, Shingo
    Narita, Shintaro
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Sato, Hiromi
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2020, 203 : E123 - E123
  • [40] The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer
    Shiota, Masaki
    Akamatsu, Shusuke
    Narita, Shintaro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Ogawa, Osamu
    Habuchi, Tomonori
    Eto, Masatoshi
    PHARMACOGENOMICS JOURNAL, 2021, 21 (04): : 440 - 445
12345